Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12
Open Access
- 10 March 2003
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 105 (3), 384-389
- https://doi.org/10.1002/ijc.11092
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Anti-oestrogenic prevention of breast cancer — the make or break pointNature Reviews Cancer, 2002
- Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu miceGene Therapy, 2002
- Estrogen receptor beta in breast cancer.Endocrine-Related Cancer, 2002
- Beyond TamoxifenAnnals of the New York Academy of Sciences, 2001
- Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccinationGene Therapy, 2001
- p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinomaInternational Journal of Cancer, 2000
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Inhibition of Angiogenesis In Vivo by Interleukin 12JNCI Journal of the National Cancer Institute, 1995
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive ImmunityAnnual Review of Immunology, 1995